Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024;19(9):1263-1285.
doi: 10.2174/011574888X179799231023060734.

Transient Fever: The Sole Treatment-Related Adverse Event Associated with Mesenchymal Stromal Cells and Solid Clues from the Real World

Yang Wang  1 , Qiuying Mou  2 , Hanxiao Yi  3 , Zilu Meng  4
Affiliations
Meta-Analysis

Transient Fever: The Sole Treatment-Related Adverse Event Associated with Mesenchymal Stromal Cells and Solid Clues from the Real World

Yang Wang et al. Curr Stem Cell Res Ther. 2024.

Abstract

Background: The number of trials investigating mesenchymal stromal cells (MSCs) soars within 3 years which urges a study analysing emerging MSC treatment-related adverse events.

Aim: To assess the safety of MSC therapy and provide solid evidence for clinical translation of MSC.

Methods: A meta-analysis of randomized clinical trials (RCTs) published up to April 20th, 2023 was performed. Odds ratio (OR) and 95% confidential intervals (CIs) were used to display pooled results.

Results: 152 randomized clinical trials (RCTs) that incorporated 9228 individuals treated with MSCs from autologous or allogenic adipose tissue, bone marrow, Wharton's Jelly, and placenta tissue were included in the analysis. We discovered appropriate 21 MSC treatment-related adverse events (TRAEs), of which fever [OR, 1.61, 95% CI: 1.22-2.11, p<0.01] was the sole event that was closely associated with MSC therapy. MSCs also trended to lower the incidence rate of tachycardia [OR, 0.83, 95% CI: 0.64-1.09, p=0.14] and fatigue [OR, 0.18, 95% CI: 0.61-1.07, p=0.18]. A separate analysis of studies with long-term follow-up (more than 1 year) demonstrated the close relationship between MSCs and fever [OR, 1.75, 95% CI: 1.26-2.24, p<0.01]. The rest TRAEs did not associate themselves with MSC therapy. Dose-response was also conducted for fever, linearity was discovered between MSCs from allogeneic tissue and Wharton's Jelly and fever.

Conclusion: To date, our results suggest that fever is the only AE closely associated with MSCs.

Keywords: MSC therapy; meta-analysis.; randomized clinical trials; safety.

PubMed Disclaimer

References

    1. Brody M.; Agronin M.; Herskowitz B.J.; Results and insights from a phase I clinical trial of Lomecel‐B for Alzheimer’s disease. Alzheimers Dement 2023,19(1),261-273 - DOI - PubMed
    1. Centeno C.; Fausel Z.; Stemper I.; Azuike U.; Dodson E.; A randomized controlled trial of the treatment of rotator cuff tears with bone marrow concentrate and platelet products compared to exercise therapy: A midterm analysis. Stem Cells Int 2020,2020,1-10 - DOI - PubMed
    1. Fathi-Kazerooni M.; Fattah-Ghazi S.; Darzi M.; Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: Clinical trial phase I and II. Stem Cell Res Ther 2022,13(1),96 - DOI - PubMed
    1. Albu S.; Kumru H.; Coll R.; Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: A randomized controlled study. Cytotherapy 2021,23(2),146-156 - DOI - PubMed
    1. Ramkisoensing A.A.; Pijnappels D.A.; Askar S.F.A.; Human embryonic and fetal mesenchymal stem cells differentiate toward three different cardiac lineages in contrast to their adult counterparts. PLoS One 2011,6(9),e24164 - DOI - PubMed

Publication types

MeSH terms